完全切除 NSCLC 患者的辅助治疗进展。
Update on adjuvant therapy in completely resected NSCLC patients.
机构信息
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
出版信息
Thorac Cancer. 2022 Feb;13(3):277-283. doi: 10.1111/1759-7714.14277. Epub 2021 Dec 12.
Abstract
In patients with completely resected non-small cell lung cancer (NSCLC), postoperative adjuvant chemotherapy has been associated with improvement in survival by minimizing the risk of recurrence. For years, systemic chemotherapy including platinum based regimen has been a mainstay treatment modality of adjuvant treatment after complete resection. ADAURA study showed that among completely resected IB to IIIA NSCLC, disease-free survival was significantly better in patients under adjuvant osimertinib than a placebo group. After the advent of a variety of new treatment regimens, such as third generation TKI and immunotherapy, the landscape of postoperative adjuvant treatment has been changing. In this review, we discuss some key issues regarding choice of adjuvant treatment after complete resection in NSCLC, and provide further updates on recent advances in treatment modalities.
摘要
在完全切除的非小细胞肺癌（NSCLC）患者中，术后辅助化疗通过降低复发风险，改善了生存。多年来，包括铂类药物在内的全身化疗一直是完全切除后辅助治疗的主要治疗方式。ADAURA 研究表明，在完全切除的 IB 期至 IIIA 期 NSCLC 患者中，与安慰剂组相比，接受辅助奥希替尼治疗的患者无疾病生存期显著更长。随着各种新的治疗方案（如第三代 TKI 和免疫治疗）的出现，术后辅助治疗的格局一直在发生变化。在这篇综述中，我们讨论了与 NSCLC 完全切除后辅助治疗选择相关的一些关键问题，并对治疗方式的最新进展进行了进一步更新。
相似文献
1
Update on adjuvant therapy in completely resected NSCLC patients.完全切除 NSCLC 患者的辅助治疗进展。
Thorac Cancer. 2022 Feb;13(3):277-283. doi: 10.1111/1759-7714.14277. Epub 2021 Dec 12.
2
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.ADAURA研究中术后化疗的使用情况及结果：奥希替尼作为切除的EGFR突变型非小细胞肺癌的辅助治疗
J Thorac Oncol. 2022 Mar;17(3):423-433. doi: 10.1016/j.jtho.2021.10.014. Epub 2021 Nov 2.
3
Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.美国社区肿瘤医疗实践中早期切除的非小细胞肺癌患者的治疗模式与卫生资源利用情况
Clin Lung Cancer. 2015 Nov;16(6):486-95. doi: 10.1016/j.cllc.2014.12.010. Epub 2014 Dec 31.
4
Overall Survival with Osimertinib in Resected -Mutated NSCLC.奥希替尼治疗可切除突变型 NSCLC 的总生存期。
N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4.
5
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.辅助阿特珠单抗治疗辅助化疗后切除的 IB-IIIA 期非小细胞肺癌（IMpower010）：一项随机、多中心、开放标签、III 期临床试验。
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
6
7
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.MAGE-A3 癌症免疫治疗作为辅助治疗在切除的 MAGE-A3 阳性非小细胞肺癌（MAGRIT）患者中的疗效：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.
8
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.术后放疗对接受辅助化疗的完全切除且处于Ⅰ期、Ⅱ期或ⅢA期非小细胞肺癌患者生存的影响：辅助长春瑞滨国际协作组（ANITA）随机试验
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701. doi: 10.1016/j.ijrobp.2008.01.044. Epub 2008 Apr 24.
9
Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).II期和III期非小细胞肺癌（NSCLC）的术后辅助化疗和放疗。
Lung Cancer. 2002 Jul;37(1):65-71. doi: 10.1016/s0169-5002(02)00026-0.
10
Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer.完全切除的早期非小细胞肺癌的术后辅助治疗。
Int J Clin Oncol. 2005 Jun;10(3):157-64. doi: 10.1007/s10147-005-0493-x.
引用本文的文献
1
The Mechanism of Steroid Hormones in Non-Small Cell Lung Cancer: From Molecular Signaling to Clinical Application.类固醇激素在非小细胞肺癌中的作用机制：从分子信号传导到临床应用
Biomedicines. 2025 Aug 15;13(8):1992. doi: 10.3390/biomedicines13081992.
2
Non-small Cell Lung Cancer, Immunotherapy and the Influence of Gut Microbiome.非小细胞肺癌、免疫疗法与肠道微生物群的影响
Curr Microbiol. 2025 Jul 29;82(9):419. doi: 10.1007/s00284-025-04408-6.
3
Adjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer: Current Advances and Future Perspectives.可切除非小细胞肺癌的辅助免疫治疗：当前进展与未来展望
Cancers (Basel). 2025 Jun 23;17(13):2099. doi: 10.3390/cancers17132099.
4
A Comprehensive Review on the Application of Artificial Intelligence for Predicting Postsurgical Recurrence Risk in Early-Stage Non-Small Cell Lung Cancer Using Computed Tomography, Positron Emission Tomography, and Clinical Data.关于使用计算机断层扫描、正电子发射断层扫描和临床数据，应用人工智能预测早期非小细胞肺癌术后复发风险的综合综述。
J Med Radiat Sci. 2025 Jan 23. doi: 10.1002/jmrs.860.
5
Construction of a cuproptosis-tricarboxylic acid cycle-associated lncRNA model to predict the prognosis of non-small cell lung cancer.构建一种与铜死亡-三羧酸循环相关的长链非编码RNA模型以预测非小细胞肺癌的预后
Transl Cancer Res. 2024 Dec 31;13(12):6807-6824. doi: 10.21037/tcr-24-660. Epub 2024 Dec 27.
6
Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study.程序性细胞死亡配体 1 表达与早期非小细胞肺癌患者切除术后临床结局的相关性：一项真实世界研究。
Curr Oncol. 2024 Oct 31;31(11):6735-6748. doi: 10.3390/curroncol31110497.
7
Preoperative respiratory assessment predicts post-operative survival in stage IA non-small cell lung cancer.术前呼吸评估可预测IA期非小细胞肺癌患者的术后生存率。
J Thorac Dis. 2024 Jun 30;16(6):3864-3872. doi: 10.21037/jtd-24-22. Epub 2024 Jun 19.
8
Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells.己酮可可碱对敏感和多药耐药非小细胞肺癌细胞的化疗增敏作用。
Cancer Drug Resist. 2024 May 20;7:19. doi: 10.20517/cdr.2024.04. eCollection 2024.
9
A Single-Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC).可切除的局部晚期非小细胞肺癌（NSCLC）联合肿瘤外科治疗的单中心经验
Diseases. 2024 May 12;12(5):98. doi: 10.3390/diseases12050098.
10
Neoadjuvant therapy for non-small cell lung cancer and esophageal cancer.非小细胞肺癌和食管癌的新辅助治疗
Am J Cancer Res. 2024 Mar 15;14(3):1258-1277. doi: 10.62347/TCEC1867. eCollection 2024.
本文引用的文献
1
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.术后放疗对完全切除术后辅助化疗的 pIIIA-N2 期非小细胞肺癌患者的影响：III 期 PORT-C 随机临床试验。
JAMA Oncol. 2021 Aug 1;7(8):1178-1185. doi: 10.1001/jamaoncol.2021.1910.
2
Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中循环肿瘤 DNA 的肿瘤初治多模态分析。
Clin Cancer Res. 2021 Aug 1;27(15):4230-4244. doi: 10.1158/1078-0432.CCR-21-0110. Epub 2021 Jun 22.
3
Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients.中国患者 II/III 期非小细胞肺癌中作为预后和预测标志物的新生抗原负荷。
Thorac Cancer. 2021 Aug;12(15):2170-2181. doi: 10.1111/1759-7714.14046. Epub 2021 Jun 15.
4
The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study.病理性淋巴结转移伴淋巴血管侵犯对临床淋巴结阴性非小细胞肺癌患者生存的影响：一项多中心研究。
Lung Cancer. 2021 Aug;158:9-14. doi: 10.1016/j.lungcan.2021.05.029. Epub 2021 May 29.
5
Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study.III 期非小细胞肺癌患者的真实世界治疗模式和临床结局：多国家观察性研究 KINDLE 的结果。
J Thorac Oncol. 2021 Oct;16(10):1733-1744. doi: 10.1016/j.jtho.2021.05.003. Epub 2021 May 26.
6
Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in -Mutant Stage III-pN2 Lung Adenocarcinoma.辅助 TKI 治疗对比 TKI 联合化疗用于 -突变 IIIB 期 pN2 肺腺癌患者的获益。
Curr Oncol. 2021 Apr 7;28(2):1424-1436. doi: 10.3390/curroncol28020135.
7
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.Ⅱ期、开放标签、单臂、多中心研究，评估阿来替尼作为可手术切除 III 期 ALK 阳性 NSCLC 的新辅助治疗的疗效和安全性：ALNEO 试验。
Clin Lung Cancer. 2021 Sep;22(5):473-477. doi: 10.1016/j.cllc.2021.02.014. Epub 2021 Feb 24.
8
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures.程序性死亡配体1表达对早期切除的非小细胞肺癌预后的影响：文献的荟萃分析
Front Oncol. 2021 Feb 23;11:567978. doi: 10.3389/fonc.2021.567978. eCollection 2021.
9
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with mutation (West Japan Oncology Group 11719L/ADJUST study).一项关于顺铂加长春瑞滨联合阿特珠单抗作为完全切除的 突变非小细胞肺癌辅助治疗的 II 期研究（日本西部肿瘤学组 11719L/ADJUST 研究）。 （注：原文中“ mutation”处信息缺失）
Ther Adv Med Oncol. 2021 Jan 21;13:1758835920987647. doi: 10.1177/1758835920987647. eCollection 2021.
10
Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.CD47 和 CD68 表达的联合预测东亚非小细胞肺癌患者的生存。
J Cancer Res Clin Oncol. 2021 Mar;147(3):739-747. doi: 10.1007/s00432-020-03477-3. Epub 2021 Jan 4.
Zotero 插件